Y-BOCS: scoring, cutoffs & interpretation

01 - What it measures

What this scale measures.

The Yale–Brown Obsessive Compulsive Scale (Y-BOCS) is a 10-item, clinician-administered, semi-structured interview that grades the severity of obsessive-compulsive symptoms over the past week. Five items rate obsessions and five rate compulsions, each across the same five dimensions: time occupied, interference with functioning, distress, resistance, and degree of control. It is preceded by a symptom checklist that establishes which obsessions and compulsions are present, so the severity ratings themselves are deliberately independent of symptom content.

That content independence is the scale's defining idea. A patient with contamination fears and one with intrusive harm-related thoughts can be compared on the same 0–40 metric, and the same patient can be tracked as symptom themes shift over treatment. The Y-BOCS measures how severe OCD is - not whether OCD is present. Diagnosis remains a clinical judgement against DSM-5 or ICD-11 criteria.

02 - Origin & purpose

Where it comes from.

The Y-BOCS was developed by Wayne Goodman, Lawrence Price, Steven Rasmussen and colleagues at Yale and Brown universities, and published in 1989 as two companion papers in the Archives of General Psychiatry - one covering development, use and reliability, the other validity. Earlier OCD measures tended to confound the number and type of symptoms with their severity; the Y-BOCS was designed so that severity could be rated on dimensions that apply to any obsession or compulsion.

It quickly became the standard primary outcome measure in OCD treatment trials, a position it still holds. A second edition (Y-BOCS-II, 2010) rescored items 0–5 (total 0–50) and integrated avoidance into the ratings, and a children's version (CY-BOCS) adapts the interview for young people - but the original 10-item, 0–40 version remains the most widely used and cited in the trial literature.

03 - Scoring & cutoffs

How scoring works.

Each of the 10 items is rated 0 (no symptoms) to 4 (extreme). Items 1–5 sum to an obsession subtotal and items 6–10 to a compulsion subtotal, each 0–20; the total ranges 0–40. Conventional severity bands are 0–7 subclinical, 8–15 mild, 16–23 moderate, 24–31 severe and 32–40 extreme. Treatment trials in OCD have most commonly required a baseline total of 16 or more for entry.

For judging change, an international expert consensus (Mataix-Cols et al., 2016) defines treatment response as a reduction of at least 35% from baseline plus a CGI-I rating of 1 or 2, and remission as a total score of 12 or less plus a CGI-S rating of 1 or 2, each sustained for at least one week.

04 - Validation evidence

How well it performs.

In the original 1989 reliability study, four raters assessed 40 patients with OCD at varying stages of treatment. Interrater agreement for the total score was excellent (intraclass correlation 0.98), every individual item also showed excellent agreement, and internal consistency averaged α = 0.89 across raters.

The companion validity paper showed Y-BOCS totals correlated significantly with independent clinician ratings of OCD severity, and the scale has repeatedly demonstrated sensitivity to change in medication and CBT trials - the property that made it the default trial endpoint. Subsequent psychometric work across translations and settings has broadly confirmed strong reliability, while also motivating the revisions made in the Y-BOCS-II.

05 - How it compares

How it compares to the alternatives.

06 - When to use it

Right tool, wrong tool.

The Y-BOCS is a severity instrument for settings that hold a licence and can give a clinician 20–30 minutes per administration. It presumes the diagnosis has already been made.

07 - Confidence & precision

Reading the score with care.

No single minimal clinically important difference in raw points is agreed for the Y-BOCS. Because the meaningfulness of a fixed point-change depends on the starting score, the consensus definitions work in percentages: a drop from 28 to 18 (36%) counts as response, while the same 10-point drop from 38 to 28 does not clear the remission bar.

Treat scores near band boundaries (e.g. 15/16, 23/24) as indicative rather than categorical, and interpret single-visit changes of a few points cautiously - the consensus criteria deliberately require the improvement to be corroborated by a global impression rating and sustained for at least a week.

08 - Limitations

What it cannot tell you.

Licensing is the practical constraint: reproduction, digitisation, EMR/app incorporation and translation all require permission or a paid agreement, which is why the questionnaire is not hosted here.

Clinically, the original version does not score avoidance directly, and the two resistance items have long been criticised - resisting obsessions is now understood to be a poor marker of severity, which is partly why the Y-BOCS-II reworked resistance and integrated avoidance. Administration takes 20–30 minutes of clinician time including the checklist, the obsession/compulsion subscale structure has been debated in factor-analytic work, and the scale rates severity only: it cannot establish or exclude a diagnosis of OCD.

09 - Licensing, explained

How licensing works.

The Y-BOCS is owned by OCD Scales, LLC. A licensing agreement is explicitly required for commercial use, EMR incorporation, inclusion in an app, digitalisation and translation, so we cannot host it. The OCI-R is a free, self-report alternative you can score here.

Common questions from clinicians

FAQ

References

Source literature.

1. [1]Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006–1011. (1989)
2. [2]Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989;46(11):1012–1016. (1989)
3. [3]Mataix-Cols D, Fernández de la Cruz L, Nordsletten AE, et al. Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder. World Psychiatry. 2016;15(1):80–81. (2016)
4. [4]Storch EA, Rasmussen SA, Price LH, et al. Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale - Second Edition. Psychol Assess. 2010;22(2):223–232. (2010)
5. [5]Foa EB, Huppert JD, Leiberg S, et al. The Obsessive-Compulsive Inventory: development and validation of a short version. Psychol Assess. 2002;14(4):485–496. (2002)